[1] Available from:http://www.who.int/cardiovascular diseases/en/.
[2] Yusuf S,Reddy S,Ounpuu S,et al.Global burden of cardiovascular disease:part Ⅱ:variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies[J].Circulation,2001,104(23):2855.
[3] Bonow RO,Smaha LA,Smith SC,et al.The international burden of cardiovascular disease: responding to the emerging global epidemic[J].Circulation 2002,106:1602.
[4] Yusuf S. Two decades of progress in preventing vascular disease[J].Lancet,2002360(9326):2.
[5] Wald NJ,Law MR.A strategy to reduce cardiovascular disease by more than 80％[J]. BMJ,2003,326(7404):1419.
[6] Jennifer GR.A"Poly-Portfolio" for Secondary Prevention: A strategy to reduce subsequent events by up to 97% over five years[J]. Am J Cardiol,2005,95(3):373.
[7] Thomas AG, Lionel HO, Milton CW.Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis[J].Lancet.2006,19:679.
[8] Vijay K, Ravi PS, Saranjit S.LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases Part 1. Separation of active components and classification of their interaction/degradation products[J].J Pharmaceut Blomed, 2008,47:508.
[9] Vijay K, Bhagwat P, Saranjit S.Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases[J].D Drug Dev. Ind. Pharm,2008,5(1): 63.
[10] Yusuf S,Pais PEffects of a polypill(Polycap)on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase 11, double-blind, randomised trial[J].Lancet, 2009,373(9672):1341.
[11] Davey SG, Ebrahim S. Folate supplementation and cardiovascular disease[J].Lancet, 2005,366:1679.
[12] Rastegarpanah M, Malekzadeh F, Thomas GN, et al.A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?[J].Archivs of Iranian Medicine, 2008,11(3):306.
[13] Salerno CM, Demopoulos L, Mukherjee R, et al.Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension[J].J Clin Hypertens,2004,6:614.
[14] Leventhal MJ, Riegel B, Carlson B, el al.Negotiating compliance in heart failure: Remaining issues and questions[J].Eur J Cardiovase Nurs,2005,4:298.
[15] Newby LK, La PNM, Chen AY, et al.Long term adherence to evidencebased secondary prevention therapies in coronary artery disease[J].Circulation,2006,113(2):203.
[16] 曹东来,扬向军.PCI术后冠心病病人他汀类药依从性分析[J].中国血液流变学杂志,2004,14(1):126.
[17] Fuster V, Voute J. MDGs: chronic diseases are not on the agenda[J].Lancet,2005,366:1512.
[18] Murray CJL, Lauer JA, Hutubessy RC, et al.Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk[J].Lancet,2003;361:717.
[19] Yusuf S, Hawken S, Ounpuu S, et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study[J].Lancet, 2004,364:937.
[20] Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials[J]. BMJ,2003,326:1427.
[21] Lonn E, Yusuf S.Polypill: the evidence and the promise[J]. CURR OPIN LIPIDOL.2009,20(6):453.
[22] Frishman WH, Ztmkerman AL.Amlodi pjne/atovrastatin: tile first cross risk factor polypill for tile prevention and treatment of caldiovaseular disease[J].Expert Prey Cardiovasc Ther,2004,2675:681.
[23] Zwolska Z, Niemirowska H, Augustynowicz E, et al.Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules[J].Int J Tuberc Lung Dis,2(10):824.
[24] Kulkanya C, Nottasorn P, Tim RC, et al.Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine[J]. AIDS,2005,19:1495.
[25] Freedberg KA, Losina E, Weinstein MC, et al.The cost effectiveness of combination antiretroviral therapy for HIV disease[J].N Engl J Med,2001,334:824.
[26] Bakshi R, Hermeling I, Gathmann I, et al.An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug[J]. T Roy Soc Trop Med H,2000,94:419.
[27] Valentin F.Prime time for a polypill after myocardial infraction[J]. Nat Clin Pract Card,2009,6:83.
[28] http://www.emea.europa.eu/htms/human/epar/a.htm.
[29] Lonn E, Yusuf S.Polypill: the evidence and the promise[J]. Curr Opin Lipidol 2009,20(6):453.
[30] Pearson TA, Blair SN, Daniels SR, et al.AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases[J].Circulation,2002,106:388.
[31] Jha P, Peto R, Zatonsky W, et al.Social inequalities in male mortality and in male mortality from smoking: indirect estimation natio from nal death rates in England and Wales, Poland, and North america[J].Lancet,2006,368:367.
[32] NCEP Expert Panel.Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III)[J].JAMA,2001,285:2486.
[33] Williams PT.Physical fitness and activity as separate heart disease risk factors: a meta-analysis[J].Med Sci Sports Exerc,2001,33:754.
[34] Blair SN, Kampert JB, Kohl HW III, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women[J].JAMA,1996,276:205.